Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Revenue (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Revenue for 3 consecutive years, with -$261000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Revenue fell 138.72% year-over-year to -$261000.0, compared with a TTM value of -$853000.0 through Dec 2024, down 163.66%, and an annual FY2024 reading of -$853000.0, down 163.66% over the prior year.
  • Revenue was -$261000.0 for Q2 2024 at Oramed Pharmaceuticals, up from -$592000.0 in the prior quarter.
  • Across five years, Revenue topped out at $904000.0 in Q4 2022 and bottomed at -$592000.0 in Q1 2024.
  • Average Revenue over 3 years is $426625.0, with a median of $670000.0 recorded in 2022.
  • The sharpest move saw Revenue changed 0.0% in 2023, then crashed 188.89% in 2024.
  • Year by year, Revenue stood at $904000.0 in 2022, then decreased by 25.44% to $674000.0 in 2023, then tumbled by 138.72% to -$261000.0 in 2024.
  • Business Quant data shows Revenue for ORMP at -$261000.0 in Q2 2024, -$592000.0 in Q1 2024, and $674000.0 in Q2 2023.